{"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"5320"}],"units":"Participants"}],"groups":[{"description":"Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.","id":"BG000","title":"T+OFS"},{"description":"Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.","id":"BG001","title":"E+OFS"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"40","upperLimit":"46","value":"44"},{"groupId":"BG001","lowerLimit":"39","upperLimit":"46","value":"43"},{"groupId":"BG002","lowerLimit":"40","upperLimit":"46","value":"43"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"Age"}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"104"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"Negative"},{"categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"96"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"Positive"}],"description":"Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.","paramType":"NUMBER","title":"Lymph-node status","unitOfMeasure":"percent of participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"119"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"<=2 cm"},{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"79"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":">=2 cm"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"unknown"}],"description":"Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.","paramType":"NUMBER","title":"Tumor size","unitOfMeasure":"percent of participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"34"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"111"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"53"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"unknown"}],"description":"Tumor grade is the histologic grade according to the BRE method. The method involves assessment of tumor morphology, including tubule formation, nuclear pleomorphism and frequency of mitoses. Grades are recorded according to criteria as 1,2 or 3. Grade 3 is associated with poor prognosis. Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.","paramType":"NUMBER","title":"Tumor grade","unitOfMeasure":"percent of participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"174"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"Negative"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"24"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"Positive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1328"},{"groupId":"BG001","value":"1332"},{"groupId":"BG002","value":"2660"}],"units":"Participants"}],"title":"Unknown"}],"description":"Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.","paramType":"NUMBER","title":"HER2 status","unitOfMeasure":"percent of participants"}],"populationDescription":"Intention-to-treat population excludes 12 patients who immediately withdrew consent, were at a non-adherent center, or had inadequate documentation of informed consent."}